Holen Sie sich die Stockscreener-App
4.58
0.33%
0.015
Handel nachbörslich:
4.58
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - Pluang
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - Yahoo Finance
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.ca
EyePoint faces securities fraud probe after tri... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - PR Newswire
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - globenewswire.com
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - Quiver Quantitative
Four retinal-disease studies are slated for Los Angeles. EyePoint will present them. - Stock Titan
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - Investing.com
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Pharmaceuticals Inc (EYPT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Eyepoint Pharmaceuticals Inc (EYPT) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT) - Seeking Alpha
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney - GlobeNewswire
EyePoint (EYPT) CFO moves 139K shares into family and annuity trusts - Stock Titan
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70% - The Economic Times
Taxes of EyePoint, Inc. – HAM:PV3B - TradingView
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) - Business Wire
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals - PR Newswire
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Stocktwits
EyePoint's Wet AMD Drug Duravyu Fails Key Late-Stage Trial - Medical Dialogues
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's Why - MarketBeat
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown (NASDAQ:EYPT) - Seeking Alpha
EyePoint: Still A Sell After Phase 3 Crash (NASDAQ:EYPT) - Seeking Alpha
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold" - MarketBeat
These Analysts Slash Their Forecasts On EyePoint - Sahm
EyePoint director Karen L. Zaderej buys $52,258 in stock - Investing.com South Africa
EyePoint director Karen Zaderej reports purchase of 10,600 shares worth $52,258 - Bitget
EyePoint (EYPT) Insider Karen Zaderej Buys 10,600 Shares, Signaling Confidence - GuruFocus
EyePoint Director Karen Zaderej Acquires 10,600 Shares in Open-Market Transaction - Kalkine Media
EyePoint director Karen L. Zaderej buys $52,258 in stock By Investing.com - Investing.com Australia
EyePoint (EYPT) director adds to stake in open‑market buy - Stock Titan
EyePoint IncInterim Phase 3 Data Shows Con - Moomoo
EYPT Maintains Buy Rating by Citigroup -- Price Target Lowered to $17.00 - GuruFocus
EyePoint Inc. (EYPT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
EYPT Stock Crashes On Duravyu Data But Catalysts Loom - StocksToTrade
Traders Buy Large Volume of Call Options on Eyepoint Pharmaceuticals (NASDAQ:EYPT) - MarketBeat
EYPT Looks 1359.7% Overvalued on GF Value™ - GuruFocus
Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
EYEPOINT INC : CITIGROUP CUTS TARGET PRICE TO $17 FROM $35 - Moomoo
EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says - marketscreener.com
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYUSlideshow - Seeking Alpha
EyePoint’s Duravyu falls short to Eylea in Phase III trial - Yahoo Finance
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal - TradingView
EyePoint rebounds despite multiple downgrades (EYPT:NASDAQ) - Seeking Alpha
RBC Capital cuts EyePoint stock rating on trial miss By Investing.com - Investing.com Australia
Chardan downgrades EyePoint stock rating on regulatory concerns By Investing.com - Investing.com South Africa
Chardan downgrades EyePoint stock rating on regulatory concerns - Investing.com Nigeria
Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more - STAT
EYPT Downgraded by Chardan Capital -- Price Target Lowered to $5.00 - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Chardan Capital to Neutral - MarketBeat
Eyepoint Pharmaceuticals' (EYPT) Sector Perform Rating Reiterated at Royal Bank Of Canada - MarketBeat
EYPT Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Earns Neutral Rating from HC Wainwright - MarketBeat
Chardan Downgrades EyePoint Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $65 - marketscreener.com
EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’ - TradingView
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):